{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:26:16Z","timestamp":1791084376025,"version":"4.1.0"},"reference-count":23,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2004,8,24]],"date-time":"2004-08-24T00:00:00Z","timestamp":1093305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2004,9]]},"abstract":"<jats:p><jats:bold>Summary:\u2002<\/jats:bold><jats:italic>Purpose:<\/jats:italic>To compare the efficacy of lamotrigine (LTG) and valproic acid (VPA) in newly diagnosed children and adolescents with typical absence seizures.<\/jats:p><jats:p><jats:italic>Methods:<\/jats:italic>A randomized<jats:bold>,<\/jats:bold>open\u2010label parallel\u2010group design was used. After undergoing an awake video\u2010EEG recording, which included one to two trials of 3 min of hyperventilation and intermittent photic stimulation, eligible patients were randomized to receive LTG or VPA. LTG was initiated at a daily dose of 0.5 mg\/kg for 2 weeks in two divided doses, followed by 1.0 mg\/kg\/day for an additional 2 weeks. Thereafter, doses were increased in 1\u2010mg\/kg\/day increments every 5 days until seizures were controlled, intolerable adverse effects occurred, or a maximum dose of 12 mg\/kg\/day had been reached. VPA was equally uptitrated according to clinical response, starting at 10 mg\/kg and increasing by 5 mg\/kg\/24 h every 3 days, if required, to a maximum of 30 mg\/kg\/day in three divided doses. Patients were seen in the clinic every month for \u226412 months.The primary efficacy end point at each visit was seizure freedom, defined as lack of clinically observed seizures since the previous visit and lack of electroclinical seizures during ambulatory 24\u2010h EEG testing and a video\u2010EEG session with hyperventilation.<\/jats:p><jats:p><jats:italic>Results<\/jats:italic>: Thirty\u2010eight children (17 boys, 21 girls), aged from 3 to 13 years (mean, 7.5 years), all newly diagnosed with childhood or juvenile typical absence seizures, were enrolled. After 1 month of treatment, 10 (52.6%) of 19 children taking VPA and one (5.3%) of 19 taking LTG were seizure free (p = 0.004). By the 3\u2010month follow\u2010up, 12 (63.1%) children taking VPA and seven (36.8%) taking LTG were controlled (p = 0.19). After 12 months, 13 children taking VPA (dose range, 20\u201330 mg\/kg\/day; mean serum level, 76.8 mg\/L; range, 51.4\u201391 mg\/L) and 10 taking LTG (dose range, 2\u201311 mg\/kg\/day; mean serum level, 8.1 mg\/L; range, 1.1\u201318 mg\/L) were seizure free (p = 0.51). Side effects were mostly mild and transient and were recorded in two (10.6%) children treated with VPA and in six (31.8%) treated with LTG.<\/jats:p><jats:p><jats:italic>Conclusions:<\/jats:italic>Both VPA and LTG can be efficacious against absence seizures, although VPA shows a much faster onset of action, at least in part because of its shorter titration schedule.<\/jats:p>","DOI":"10.1111\/j.0013-9580.2004.40903.x","type":"journal-article","created":{"date-parts":[[2004,8,24]],"date-time":"2004-08-24T08:02:23Z","timestamp":1093334543000},"page":"1049-1053","source":"Crossref","is-referenced-by-count":90,"title":["Lamotrigine versus Valproic Acid as First\u2010line Monotherapy in Newly Diagnosed Typical Absence Seizures: An Open\u2010label, Randomized, Parallel\u2010group Study"],"prefix":"10.1111","volume":"45","author":[{"given":"Giangennaro","family":"Coppola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranca","family":"Auricchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Carotenuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pascotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,8,24]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.1982.tb13703.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.32.2.157"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.4.949"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.25.6.515"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1985.tb10994.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1994.tb02445.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1995.tb00434.x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/0883073897012001081"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb00805.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1684\/j.1950-6945.1999.tb00315.x","article-title":"Efficacy of lamotrigine in idiopathic generalized epilepsy syndromes: a video\u2010EEG\u2010controlled, open study","volume":"1","author":"Gericke CA","year":"1999","journal-title":"Epileptic Disord"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0387-7604(99)00023-6"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-8994(00)00162-4"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200003000-00005"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb00807.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128072-200103050-00006"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1981.tb06159.x"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200216100-00004"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199447020-00008"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.28.9.886"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1988.tb03759.x"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2001.28899.x"},{"issue":"5","key":"e_1_2_5_23_2","first-page":"149","article-title":"Consensus guidelines: preconception counseling, management, and care of the pregnant woman with epilepsy","volume":"42","author":"Delgado\u2010Escueta AV","year":"1992","journal-title":"Neurology"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2001.042007941.x"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.0013-9580.2004.40903.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.0013-9580.2004.40903.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T10:18:37Z","timestamp":1734517117000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.0013-9580.2004.40903.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8,24]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["10.1111\/j.0013-9580.2004.40903.x"],"URL":"https:\/\/doi.org\/10.1111\/j.0013-9580.2004.40903.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,8,24]]}}}